Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications

The Breast : Official Journal of the European Society of Mastology
Nadia Harbeck

Abstract

Until recently, due to its aggressive clinical behavior, HER2-positive disease has been considered as a single breast cancer subtype and treated accordingly, particularly in early breast cancer (eBC). Based on the pivotal trial data from the metastatic breast cancer setting, anti-HER2 therapy in eBC has been developed as a one size fits all approach with a chemotherapy backbone independently of tumor endocrine sensitivity. Yet, recent data demonstrated different response rates after neoadjuvant chemotherapy + HER2-targeted therapy for hormone-receptor (HR) negative vs. HR-positive tumors. Pathological complete response seems to have a different impact on patient outcome according to HER2-subtype with the strongest correlation found in HR-negative disease. Moreover, substantial preclinical and emerging clinical data in breast cancer suggest that there is a crosstalk between endocrine and HER2 pathways conferring resistance to agents targeting either pathway and suggesting co-targeted approaches. Early clinical results indicate meaningful pathological response rates by co-targeted approaches against ER and HER2. The big challenge for HER2-positive eBC in the upcoming years will be to individualize anti-HER2 therapy according to e...Continue Reading

References

Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Jan 17, 2003·Journal of the National Cancer Institute·Gottfried KonecnyDennis J Slamon
Jul 6, 2007·The New England Journal of Medicine·Clifford A Hudis
Feb 26, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M UntchUNKNOWN HERA Study Team
Jan 20, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A U Buzdar
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JohnstonMark Pegram
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Jul 23, 2013·Lancet·Aron GoldhirschUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Aug 21, 2014·Journal of the National Cancer Institute·Aleix PratJosé Baselga
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
Jan 8, 2015·The New England Journal of Medicine·Sara M TolaneyEric P Winer

❮ Previous
Next ❯

Citations

Nov 19, 2019·Frontiers in Oncology·Ana Godoy-OrtizEmilio Alba
Mar 8, 2018·Breast Cancer : Basic and Clinical Research·John SyriosAnna Koumarianou
Feb 3, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Ayaka KatayamaEmad A Rakha
Apr 8, 2020·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Yun Shin ChunJean-Nicolas Vauthey
Jan 16, 2021·Breast Care·Marija BanEduard Vrdoljak

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved